About YU


YU's Professor JANG Jae-hoon’s Research Team Selected for STEAM Research Project N

  • Writer PR team
  • Date : 2024.07.10 10:44
  • Publication Date : 2024.06.21
  • Views : 492

STEAM Research Project ‘Future Pioneers of Promising Convergence Technologies’ Initiative by the Ministry of Science and ICT

Collaborative Research with the Department of Pharmacy for Phase 1

Plans to Develop Next-Generation Amino Acid-Based Lipid Nanoparticle Cancer Immunotherapy Vaccines

[June 21, 2024]

<Professor JANG Jae-hoon of YU’s Department of Pharmacy>

 YU (President CHOI Oe-chool) has been selected for the Ministry of Science and ICT's STEAM (Science, Technology, Engineering, Arts, Mathematics) research project under the ‘Future Pioneers of Promising Convergence Technologies’ initiative.

 The Future Pioneers of Promising Convergence Technologies project supports the development of mission-driven core technologies that can create and lead new technology and industry paradigms. The challenge-type project selected this time is particularly aimed at supporting convergence research to solve unexplored scientific challenges.

 Professor JANG Jae-hoon’s ‘T Cell Neo-Signal Transduction Research Team’ will lead a project to identify new amino acid-mediated signal transduction pathways in T cells and develop amino acid-based cancer immunotherapy vaccines.The research will be conducted in three phases over 5 years and 9 months, with potential funding of up to 4.7 billion KRW based on stage evaluations.Phase 1 will involve collaborative research with the Department of Pharmacy at YU.

 Professor JANG stated, “We aim to propose a new immunological dogma and develop next-generation amino acid-based lipid nanoparticle cancer immunotherapy vaccines to secure fundamental technology. This project selection marks an important starting point, and we hope to contribute to the advancement of the bio-pharmaceutical industry through our research outcomes.”

 Professor JANG has recently published research results in prestigious journals such as Nature Communications (IF: 16.6), Molecular Cancer (IF: 37.3), and Experimental & Molecular Medicine (IF: 12.8), earning recognition for his research excellence.